Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2016, Article ID 2469523, 10 pages
http://dx.doi.org/10.1155/2016/2469523
Review Article

Beyond DNA: An Integrated and Functional Approach for Classifying Germline Variants in Breast Cancer Genes

Ambry Genetics Corp., 15 Argonaut, Aliso Viejo, CA 92656, USA

Received 4 June 2016; Revised 4 September 2016; Accepted 19 September 2016

Academic Editor: Zsuzsanna Kahán

Copyright © 2016 T. Pesaran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. LaDuca, A. J. Stuenkel, J. S. Dolinsky et al., “Utilization of multigene panels in hereditary cancer predisposition testing: analysis of more than 2,000 patients,” Genetics in Medicine, vol. 16, no. 11, pp. 830–837, 2014. View at Publisher · View at Google Scholar · View at Scopus
  2. M. B. Daly, J. E. Axilbund, S. Buys et al., “Genetic/familial high-risk assessment: breast and ovarian,” The National Comprehensive Cancer Network, vol. 8, pp. 562–594, 2010. View at Google Scholar
  3. “National Comprehensive Cancer Network Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 2.2016),” 2016, https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf
  4. M. Magrane and UniProt Consortium, “UniProt knowledgebase: a hub of integrated protein data,” Database, vol. 2011, Article ID bar009, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. H. M. Berman, J. Westbrook, Z. Feng et al., “The protein data bank,” Nucleic Acids Research, vol. 28, no. 1, pp. 235–242, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. W. C. Lau, Y. Li, Z. Liu, Y. Gao, Q. Zhang, and M. S. Huen, “Structure of the human dimeric ATM kinase,” Cell Cycle, vol. 15, no. 8, pp. 1117–1124, 2016. View at Publisher · View at Google Scholar
  7. S. Richards, N. Aziz, S. Bale et al., “Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology,” Genetics in Medicine, vol. 17, no. 5, pp. 405–424, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. C. S. Richards, S. Bale, D. B. Bellissimo et al., “ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007,” Genetics in Medicine, vol. 10, no. 4, pp. 294–300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. V. Tavtigian, M. S. Greenblatt, D. E. Goldgar, and P. Boffetta, “Assessing pathogenicity: overview of results from the IARC unclassified genetic variants working group,” Human Mutation, vol. 29, no. 11, pp. 1261–1264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. K. N. Maxwell, S. N. Hart, J. Vijai et al., “Evaluation of ACMG-guideline-based variant classification of cancer susceptibility and non-cancer-associated genes in families affected by breast cancer,” The American Journal of Human Genetics, vol. 98, no. 5, pp. 801–817, 2016. View at Publisher · View at Google Scholar
  11. K. D. Gonzalez, C. H. Buzin, K. A. Noltner et al., “High frequency of de novo mutations in Li-Fraumeni syndrome,” Journal of Medical Genetics, vol. 46, no. 10, pp. 689–693, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Mester and C. Eng, “Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome,” Genetics in Medicine, vol. 14, no. 9, pp. 819–822, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. D. R. Walker, J. P. Bond, R. E. Tarone et al., “Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features,” Oncogene, vol. 18, no. 1, pp. 211–218, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Lek, K. J. Karczewski, E. V. Minikel et al., “Analysis of protein-coding genetic variation in 60,706 humans,” Nature, vol. 536, no. 7616, pp. 285–291, 2016. View at Publisher · View at Google Scholar
  15. F. P. Li, J. F. Fraumeni Jr., J. J. Mulvihill et al., “A cancer family syndrome in twenty-four kindreds,” Cancer Research, vol. 48, no. 18, pp. 5358–5362, 1988. View at Google Scholar · View at Scopus
  16. D. Pruss, B. Morris, E. Hughes et al., “Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes,” Breast Cancer Research and Treatment, vol. 147, no. 1, pp. 119–132, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. L. Guidugli, V. S. Pankratz, N. Singh et al., “A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity,” Cancer Research, vol. 73, no. 1, pp. 265–275, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Karam, J. Wengrod, L. B. Gardner, and M. F. Wilkinson, “Regulation of nonsense-mediated mRNA decay: implications for physiology and disease,” Biochimica et Biophysica Acta—Gene Regulatory Mechanisms, vol. 1829, no. 6-7, pp. 624–633, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Anczuków, M. D. Ware, M. Buisson et al., “Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins?” Human Mutation, vol. 29, no. 1, pp. 65–73, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Jian, E. Boerwinkle, and X. Liu, “In silico tools for splicing defect prediction: a survey from the viewpoint of end users,” Genetics in Medicine, vol. 16, no. 7, pp. 497–503, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Houdayer, V. Caux-Moncoutier, S. Krieger et al., “Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants,” Human Mutation, vol. 33, no. 8, pp. 1228–1238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. M. P. G. Vreeswijk, J. N. Kraan, H. M. van der Klift et al., “Intronic variants in BRCA1 and BRCA2 that affect RNA splicing can be reliably selected by splice-site prediction programs,” Human Mutation, vol. 30, no. 1, pp. 107–114, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. P. J. Whiley, M. de la Hoya, M. Thomassen et al., “Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practice in standardized clinical testing,” Clinical Chemistry, vol. 60, no. 2, pp. 341–352, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. G. A. Millot, M. A. Carvalho, S. M. Caputo et al., “A guide for functional analysis of BRCA1 variants of uncertain significance,” Human Mutation, vol. 33, no. 11, pp. 1526–1537, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. D. J. R. Ransburgh, N. Chiba, C. Ishioka, A. E. Toland, and J. D. Parvin, “Identification of breast tumor mutations in BRCA1 that abolish its function in homologous DNA recombination,” Cancer Research, vol. 70, no. 3, pp. 988–995, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Lu, M. Xie, M. C. Wendl et al., “Patterns and functional implications of rare germline variants across 12 cancer types,” Nature Communications, vol. 6, Article ID 10086, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Scully, S. Ganesan, K. Vlasakova, J. Chen, M. Socolovsky, and D. M. Livingston, “Genetic analysis of BRCA1 function in a defined tumor cell line,” Molecular Cell, vol. 4, no. 6, pp. 1093–1099, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. W. W. Y. Au and B. R. Henderson, “The BRCA1 RING and BRCT domains cooperate in targeting BRCA1 to ionizing radiation-induced nuclear foci,” The Journal of Biological Chemistry, vol. 280, no. 8, pp. 6993–7001, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Rodriguez, W. W. Y. Au, and B. R. Henderson, “Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain,” Experimental Cell Research, vol. 293, no. 1, pp. 14–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Drost, P. Bouwman, S. Rottenberg et al., “BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance,” Cancer Cell, vol. 20, no. 6, pp. 797–809, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. K. A. T. Naipal, N. S. Verkaik, N. Ameziane et al., “Functional Ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment,” Clinical Cancer Research, vol. 20, no. 18, pp. 4816–4826, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. A. N. A. Monteiro, A. August, and H. Hanafusa, “Evidence for a transcriptional activation function of BRCA1 C-terminal region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 24, pp. 13595–13599, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Vallon-Christersson, C. Cayanan, K. Haraldsson et al., “Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families,” Human Molecular Genetics, vol. 10, no. 4, pp. 353–360, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. C. M. Phelan, V. Dapic, B. Tice et al., “Classification of BRCA1 missense variants of unknown clinical significance,” Journal of Medical Genetics, vol. 42, no. 2, pp. 138–146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. A. Carvalho, S. M. Marsillac, R. Karchin et al., “Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis,” Cancer Research, vol. 67, no. 4, pp. 1494–1501, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. P. S. Brzovic, J. R. Keeffe, H. Nishikawa et al., “Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 10, pp. 5646–5651, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. J. R. Morris, L. Pangon, C. Boutell, T. Katagiri, N. H. Keep, and E. Solomon, “Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility,” Human Molecular Genetics, vol. 15, no. 4, pp. 599–606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. S. T. South, C. Lee, A. N. Lamb et al., “ACMG standards and guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013,” Genetics in Medicine, vol. 15, no. 11, pp. 901–909, 2013. View at Google Scholar
  39. M. S. Lee, R. Green, S. M. Marsillac et al., “Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays,” Cancer Research, vol. 70, no. 12, pp. 4880–4890, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Kallioniemi, O.-P. Kallioniemi, D. Sudar et al., “Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors,” Science, vol. 258, no. 5083, pp. 818–821, 1992. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Pinkel and D. G. Albertson, “Array comparative genomic hybridization and its applications in cancer,” Nature Genetics, vol. 37, no. 6, supplement, pp. S11–S17, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Saillour, M. Cossée, F. Leturcq et al., “Detection of exonic copy-number changes using a highly efficient oligonucleotide-based comparative genomic hybridization-array method,” Human Mutation, vol. 29, no. 9, pp. 1083–1090, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Staaf, T. Törngren, E. Rambech et al., “Detection and precise mapping of germline rearrangements in BRCA1, BRCA2, MSH2, and MLH1 using zoom-in array comparative genomic hybridization (aCGH),” Human Mutation, vol. 29, no. 4, pp. 555–564, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. T. A. Peterson, E. Doughty, and M. G. Kann, “Towards precision medicine: advances in computational approaches for the analysis of human variants,” Journal of Molecular Biology, vol. 425, no. 21, pp. 4047–4063, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Choi, G. E. Sims, S. Murphy, J. R. Miller, and A. P. Chan, “Predicting the functional effect of amino acid substitutions and indels,” PLoS ONE, vol. 7, no. 10, Article ID e46688, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Stefl, H. Nishi, M. Petukh, A. R. Panchenko, and E. Alexov, “Molecular mechanisms of disease-causing missense mutations,” Journal of Molecular Biology, vol. 425, no. 21, pp. 3919–3936, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. T. G. Kucukkal, Y. Yang, S. C. Chapman, W. Cao, and E. Alexov, “Computational and experimental approaches to reveal the effects of single nucleotide polymorphisms with respect to disease diagnostics,” International Journal of Molecular Sciences, vol. 15, no. 6, pp. 9670–9717, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. B. M. Kroncke, C. G. Vanoye, J. Meiler, A. L. George Jr., and C. R. Sanders, “Personalized biochemistry and biophysics,” Biochemistry, vol. 54, no. 16, pp. 2551–2559, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Reumers, J. Schymkowitz, and F. Rousseau, “Using structural bioinformatics to investigate the impact of non synonymous SNPs and disease mutations: scope and limitations,” BMC Bioinformatics, vol. 10, supplement 8, article S9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Casadio, M. Vassura, S. Tiwari, P. Fariselli, and P. Luigi Martelli, “Correlating disease-related mutations to their effect on protein stability: a large-scale analysis of the human proteome,” Human Mutation, vol. 32, no. 10, pp. 1161–1170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. D. E. V. Pires, J. Chen, T. L. Blundell, and D. B. Ascher, “In silico functional dissection of saturation mutagenesis: interpreting the relationship between phenotypes and changes in protein stability, interactions and activity,” Scientific Reports, vol. 6, Article ID 19848, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Karchin, M. Agarwal, A. Sali, F. Couch, and M. S. Beattie, “Classifying variants of undetermined significance in BRCA2 with protein likelihood ratios,” Cancer Informatics, vol. 6, pp. 203–216, 2008. View at Google Scholar · View at Scopus
  53. A. A. Yee, A. Savchenko, A. Ignachenko et al., “NMR and X-ray crystallography, complementary tools in structural proteomics of small proteins,” Journal of the American Chemical Society, vol. 127, no. 47, pp. 16512–16517, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. R. D. Finn, P. Coggill, R. Y. Eberhardt et al., “The Pfam protein families database: towards a more sustainable future,” Nucleic Acids Research, vol. 44, no. 1, pp. D279–D285, 2016. View at Publisher · View at Google Scholar
  55. S. Hunter, R. Apweiler, T. K. Attwood et al., “InterPro: the integrative protein signature database,” Nucleic Acids Research, vol. 37, no. 1, pp. D211–D215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. J. A. Clapperton, I. A. Manke, D. M. Lowery et al., “Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer,” Nature Structural & Molecular Biology, vol. 11, no. 6, pp. 512–518, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. S. L. Clark, A. M. Rodriguez, R. R. Snyder, G. D. V. Hankins, and D. Boehning, “Structure-function of the tumor suppressor BRCA1,” Computational and Structural Biotechnology Journal, vol. 1, no. 1, pp. 1–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. R. S. Williams, R. Green, and J. N. M. Glover, “Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1,” Nature Structural Biology, vol. 8, no. 10, pp. 838–842, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. R. S. Williams, M. S. Lee, D. D. Hau, and J. N. M. Glover, “Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1,” Nature Structural & Molecular Biology, vol. 11, no. 6, pp. 519–525, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. P. J. E. Rowling, R. Cook, and L. S. Itzhaki, “Toward classification of BRCA1 missense variants using a biophysical approach,” The Journal of Biological Chemistry, vol. 285, no. 26, pp. 20080–20087, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. J. N. M. Glover, “Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain,” Familial Cancer, vol. 5, no. 1, pp. 89–93, 2006. View at Publisher · View at Google Scholar · View at Scopus